Thursday, January 17, 2013
Publication and contact
Assays & screens
combinatorial screening to identify genotype-selective combination therapies
combinatorial screening could be useful for identifying genotype-selective
combination therapies to treat melanoma. The combinatorial screen tested a
curated panel of 150 small molecule chemotherapy or targeted therapies
against melanomas with activating mutations in BRAF
or those with wild-type forms of the genes. Inhibition of both epidermal
growth factor receptor (EGFR)
kinase B (PKB; PKBA;
sensitized treatment-resistant BRAF mutant melanomas to Zelboraf
vemurafenib. The screen also found that Ras-mutant
melanomas were sensitive to the combination of statins
dependent kinase (CDK) inhibitors. Next steps include
running additional animal studies.
Pharmaceutical Co. Ltd. and Daiichi
Sankyo Co. Ltd. market the BRAF inhibitor Zelboraf to treat
Published online Jan. 17, 2013
status not applicable
Held, M.A. et al. Cancer
Discov.; published online Dec. 13, 2012;
Contact: David F. Stern, Yale School of Medicine, New Haven,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]